What is Maze Therapeutics?
Maze Therapeutics operates at the intersection of advanced human genetics and drug discovery. The company is dedicated to developing novel, small molecule precision medicines designed to address the underlying causes of complex diseases, including obesity and cardiovascular disorders. By utilizing a proprietary platform that interprets genetic data, Maze identifies high-impact targets that were previously considered undruggable. This scientific rigor has positioned the company as a formidable player in the biopharmaceutical landscape, effectively bridging the gap between genomic insights and clinical application to improve patient outcomes in high-need therapeutic areas.
How much funding has Maze Therapeutics raised?
Maze Therapeutics has raised a total of $496M across 3 funding rounds:
Series A
$191M
Unspecified
$190M
Series D
$115M
Series A (2019): $191M with participation from Third Rock Ventures and ARCH Venture Partners
Unspecified (2022): $190M led by Casdin Capital, a16z Bio+Health, Woodline Partners, General Catalyst, and Matrix Capital Management
Series D (2024): $115M supported by Frazier Life Sciences Management, Deep Track Capital, Logos Capital Partners Sa rl, and Janus Henderson Investors
Key Investors in Maze Therapeutics
Frazier Life Sciences Management
A longstanding biotech investment firm that employs both venture and public strategies to partner with and build companies focused on developing novel therapeutics.
Deep Track Capital
An investment firm located in Greenwich, Connecticut, that specializes exclusively in the life sciences and biotechnology industry.
Logos Capital Partners Sa rl
A business management and financial oversight firm providing operational leadership and strategic support to growing enterprises.
What's next for Maze Therapeutics?
With the recent capital deployment, Maze Therapeutics is well-positioned to accelerate its clinical development programs and expand its precision medicine portfolio. The strategic focus will likely shift toward advancing lead candidates through late-stage trials while refining its genetic discovery engine. As the company matures, the emphasis will remain on operational excellence and the translation of complex genetic findings into scalable, market-ready therapies. This trajectory suggests a continued commitment to building an enduring enterprise capable of reshaping the standard of care for patients suffering from chronic metabolic and cardiovascular diseases.
See full Maze Therapeutics company page
